Here, we determined the correlations of CD93 high expression levels with pernicious pathology types, unsatisfactory survival, neoplasm-infiltrated immunocytes, and immunosuppressive processes among gliomas, thus identifying CD93 as an encouraging marker and likely target for glioma-based precise diagnosis, therapies, and prognosis evaluations. This evidence concerns the gene CD93 and central nervous system cancer.